`
`__________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`__________
`
`REGENERON PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVARTIS PHARMA AG,
`NOVARTIS TECHNOLOGY LLC,
`NOVARTIS PHARMACEUTICALS CORPORATION,
`Patent Owners
`
`__________
`
`Case IPR2021-00816
`U.S. Patent 9,220,631
`
`__________
`
`PATENT OWNERS’ UPDATED MANDATORY NOTICES
`
`
`
`Case IPR2021-00816
`U.S. Patent 9,220,631
`Pursuant to 37 C.F.R. § 42.8(a)(3), Patent Owners Novartis Pharma AG,
`
`Novartis Technology LLC, and Novartis Pharmaceuticals Corporation
`
`(collectively, “Patent Owner”) hereby updates its Mandatory Notices to update
`
`the identification of counsel and service information.
`
`I.
`
`37 C.F.R. § 42.8(b)(1) – REAL PARTY-IN-INTEREST
`
`The patent owners and real parties-in-interest are Novartis Pharma
`
`AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation.
`
`II.
`
`37 C.F.R. § 42.8(b)(2) – RELATED MATTERS
`
`Pursuant to 37 C.F.R. § 42.8(b)(2), Patent Owners identify the following
`
`district court and administrative proceedings that would affect, or may be
`
`affected by, a decision in this proceeding:
`
` Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., No. 1:20-
`
`cv- 00690-TJM-CFH (NDNY)
`
` Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG et al, 1:21-
`
`cv-01066-DNH-CFH (NDNY)
`
` International Trade Commission Inv. No. 337-1207, Certain Pre-
`
`Filled Syringes for Intravitreal Injection and Components Thereof
`
` IPR2020-01317 (Patent No. 9,220,631), Regeneron Pharmaceuticals, Inc.
`
`v. Novartis Pharma AG, et al.
`
`1
`
`
`
`Case IPR2021-00816
`U.S. Patent 9,220,631
`
` IPR2020-01318 (Patent No. 9,220,631), Regeneron Pharmaceuticals, Inc.
`v. Novartis Pharma AG, et al.
`
`III.
`
`37 C.F.R. § 42.8(b)(3) – DISCLOSURE OF COUNSEL
`
`Pursuant to 37 C.F.R. § 42.8(b)(3), Patent Owner identifies lead and back-
`
`up counsel as follows:
`
`Lead Counsel:
`
`First Backup Counsel:
`
`Elizabeth J. Holland (Reg. No. 47,657)
`ALLEN & OVERY LLP
`221 Avenue of the Americas
`New York, NY 10020
`Phone: (212) 610-6300
`elizabeth.holland@allenovery.com
`
`Nicholas K. Mitrokostas (pro hac vice)
` ALLEN & OVERY LLP
`1 Beacon Street
`Boston, MA 02108
`Phone: (857) 353-4503
`nicholas.mitrokostas@allenovery.com
`
`Backup Counsel:
`
`William G. James (Reg. No. 55,931)
`ALLEN & OVERY LLP
`1101 New York Ave, N.W.
`Washington, D.C. 20005
`Phone: (202) 683-3800
`william.james@allenovery.com
`
`IV.
`
`37 C.F.R. § 42.8(b)(4) – CORRESPONDENCE
`
`Pursuant to 37 C.F.R. § 42.8(b)(4), Patent Owners request that all
`2
`
`
`
`Case IPR2021-00816
`U.S. Patent 9,220,631
`electronic correspondence be directed to lead counsel and back-up counsel
`
`identified in Section III above. Patent Owner consents to electronic service at
`
`the following e- mail address: elizabeth.holland@allenovery.com,
`
`nicholas.mitrokostas@allenovery.com and william.james@allenovery.com.
`
`Dated: July 13, 2022
`
`By:
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`ALLEN & OVERY LLP
`221 Avenue of the Americas
`New York, NY 10020
`Tel: (212) 610-6300
`elizabeth.holland@allenovery.com
`
`Attorney for Patent Owners
`
`3
`
`
`
`Case IPR2021-00816
`U.S. Patent 9,220,631
`
`CERTIFICATE OF SERVICE
`A copy of this Patent Owners’ Updated Mandatory Notices has been
`
`served on Petitioner’s attorneys of record as follows via electronic mail:
`
`Elizabeth Stotland Weiswasser
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
` T: 212-310-8022
`F: 212-310-8007
`elizabeth.weiswasser@weil.com
`USPTO Reg. No. 55,721
`Anish R. Desai
`Weil, Gotshal & Manges LLP
`767 Fifth Avenue
`New York, NY 10153
` T: 212-310-8730
`F: 212-310-8007
`anish.desai@weil.com
`USPTO Reg. No. 73,760
`
`Natalie Kennedy
`Weil, Gotshal & Manges LLP
` 767 Fifth Avenue
`New York, NY 10153
` T: 212-310-8730
`F: 212-310-8007
`natalie.kennedy@weil.com
`USPTO Reg. No. 68,511
`Andrew Gesior
`Weil, Gotshal & Manges LLP
` 767 Fifth Avenue
`New York, NY 10153
` T: 212-310-8730
`F: 212-310-8007
`andrew.gesior@weil.com
`
`
`
`Case IPR2021-00816
`U.S. Patent 9,220,631
`
`USPTO Reg. No. 76,588
`
`Christopher M. Pepe
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`christopher.pepe@weil.com
`USPTO Reg. No. 73,851
`
`Matthew D. Sieger
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`matthew.sieger@weil.com
`USPTO Reg. No. 76,051
`
`Priyata Y. Patel
`Weil, Gotshal & Manges LLP
`2001 M Street, N.W., Suite 600
`Washington, D.C. 20036
`T: 202-682-7000
`F: 202-857-0940
`priyata.patel@weil.com
`USPTO Reg. No. 76,861
`
`Regeneron.IPR.Service@weil.com
`
`Petra Scamborova
`Regeneron Pharmaceuticals, Inc.
`777 Old Saw Mill River Road
`Tarrytown, NY 10591
`T: 914-847-7611
`petra.scamborova@regeneron.com
`Admitted pro hac vice
`
`
`
`Case IPR2021-00816
`U.S. Patent 9,220,631
`
`James T. Evans
`Regeneron Pharmaceuticals, Inc.
`777 Old Saw Mill River Road
`Tarrytown, NY 10591
`T: 914-847-7000
`james.evans@regeneron.com
`USPTO Reg. No. 64,377
`
`Attorneys for Regeneron Pharmaceuticals, Inc.
`
`Dated: July 13, 2022
`
`By:
`
`/Elizabeth J. Holland/
`Elizabeth J. Holland (Reg. No. 47,657)
`Lead Counsel for Patent Owners
`Goodwin Procter LLP
`620 Eighth Avenue New York, NY 10018
`Phone: (212) 813-8800
`Fax: (212) 355-3333
`EHolland@goodwinlaw.com
`
`